A study tests multivalent display of an E. coli adhesin on I53-50 protein nanoparticles to boost vaccine immunogenicity and simplify formulation.
Key Takeaways
- Urinary tract infections, caused primarily by uropathogenic E
- Coli , are a significant public health burden, affecting approximately 50% of women worldwide
- Adhesin FimH is responsible for host receptor binding and is therefore a promising vaccine candidate